SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Pharming Group N.V.

SG&A Expenses: Jazz vs. Pharming's Strategic Insights

__timestampJazz Pharmaceuticals plcPharming Group N.V.
Wednesday, January 1, 20144061140004042025
Thursday, January 1, 20154491190005279557
Friday, January 1, 20165028920008073913
Sunday, January 1, 201754415600044864073
Monday, January 1, 201868353000053488904
Tuesday, January 1, 201973694200065896361
Wednesday, January 1, 202085423300069968267
Friday, January 1, 2021145168300092047281
Saturday, January 1, 20221416967000131819000
Sunday, January 1, 2023134310500087501000
Loading chart...

Infusing magic into the data realm

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Jazz Pharmaceuticals plc and Pharming Group N.V. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Jazz Pharmaceuticals saw a steady increase in SG&A expenses, peaking at approximately $1.45 billion in 2021, a 257% increase from 2014. In contrast, Pharming Group N.V. maintained a more modest growth, with expenses rising from $4 million in 2014 to $132 million in 2022, marking a 3,170% increase. This disparity highlights Jazz's aggressive expansion strategy compared to Pharming's more conservative approach. As the industry evolves, understanding these financial strategies provides valuable insights into each company's operational efficiency and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025